How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/complicated-urinary-tract-infections.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-09 · How we verify

complicated urinary tract infections — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

complicated urinary tract infections (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating complicated urinary tract infections, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Test formulation (Treatment A)	test-formulation-treatment-a	Pfizer	Enzyme inhibitor	Specific enzyme	Not yet determined
Xerava	ERAVACYCLINE	Tetraphase Pharms			2019-01-01
Doribax	DORIPENEM	Shionogi	Penem Antibacterial		2007-01-01
Levaquin	levofloxacin	Generic (originally Daiichi Sankyo/J&J)	Fluoroquinolone Antibacterial [EPC]	CAAX prenyl protease 2, Multidrug and toxin extrusion protein 1, Potassium voltage-gated channel subfamily H member 2	1996-12-20
Maxipime	CEFEPIME	Baxter	Cephalosporin Antibacterial		1996-01-01
Maxipime	Cefepime Hydrochloride	Baxter	Cephalosporin	Bacterial cell wall peptidoglycan	1996-01-01
Arikayce Kit	AMIKACIN	Bristol-Myers Squibb	Aminoglycoside Antibacterial		1981-01-01
Vantobra	Tobramycin Sulfate	Pfizer	tobramycin	Taste receptor type 2 member 20	1974-01-01
Garamycin	GENTAMICIN	Merck & Co.	Aminoglycoside Antibacterial	Transient receptor potential cation channel subfamily V member 5	1970-01-01
Gentamicin	Gentamicin Sulfate	Merck & Co.	gentamicin	Dihydrofolate reductase	1970-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 5 drugs in complicated urinary tract infections
Pfizer · 3 drugs in complicated urinary tract infections
Merck & Co. · 2 drugs in complicated urinary tract infections
Baxter · 2 drugs in complicated urinary tract infections
Novartis · 1 drug in complicated urinary tract infections
Shionogi · 1 drug in complicated urinary tract infections
Tetraphase Pharms · 1 drug in complicated urinary tract infections
University Hospital Tuebingen · 1 drug in complicated urinary tract infections
University Hospital, Lille · 1 drug in complicated urinary tract infections
Assistance Publique - Hôpitaux de Paris · 1 drug in complicated urinary tract infections
Bristol-Myers Squibb · 1 drug in complicated urinary tract infections
Generic (originally Daiichi Sankyo/J&J) · 1 drug in complicated urinary tract infections

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in complicated urinary tract infections:

Cite this brief

Drug Landscape (2026). complicated urinary tract infections — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/complicated-urinary-tract-infections. Accessed 2026-06-09.

complicated urinary tract infections full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing